S2L Stock Overview
Operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Bausch + Lomb Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.20 |
| 52 Week High | US$18.60 |
| 52 Week Low | US$12.50 |
| Beta | 0.47 |
| 1 Month Change | -2.94% |
| 3 Month Change | -14.84% |
| 1 Year Change | -25.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| S2L | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.2% | 0.3% | -0.9% |
| 1Y | -25.0% | -1.7% | 4.5% |
Return vs Industry: S2L underperformed the German Medical Equipment industry which returned -1.7% over the past year.
Return vs Market: S2L underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| S2L volatility | |
|---|---|
| S2L Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: S2L has not had significant price volatility in the past 3 months.
Volatility Over Time: S2L's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1853 | 13,300 | Brent Saunders | www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Bausch + Lomb Corporation Fundamentals Summary
| S2L fundamental statistics | |
|---|---|
| Market cap | €4.74b |
| Earnings (TTM) | -€311.42m |
| Revenue (TTM) | €3.99b |
1.2x
P/S Ratio-15.3x
P/E RatioIs S2L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S2L income statement (TTM) | |
|---|---|
| Revenue | US$4.31b |
| Cost of Revenue | US$1.69b |
| Gross Profit | US$2.62b |
| Other Expenses | US$2.96b |
| Earnings | -US$337.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 60.73% |
| Net Profit Margin | -7.81% |
| Debt/Equity Ratio | 68.1% |
How did S2L perform over the long term?
See historical performance and comparison